Floatz logo

SIMVASTATIN

Lacunar Anterior Circulation Infarct

Dexa Medica GroupSmall moleculePhase 2/3Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Lacunar Anterior Circulation Infarct cohort.

Asset / SponsorPhaseRating
Citicholine
Dexa Medica Group
Phase 2/3CCC
Dlbs1033
Dexa Medica Group
Phase 2/3CC

Same molecule, other indications

SIMVASTATIN is also rated in:

HypercholesterolemiaDormant
BBB
Indicative ·
76 / 100
View asset →
psychotic disorderDormant
BBB
Indicative ·
75 / 100
View asset →
inherited lipid metabolism disorderDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →